Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort
Article in Nature Communications (February 2024)
The most recent citing publications are shown below. View all 10 publications that cite this research output on Dimensions.
Article in Nature Communications (February 2024)
Article in Cell Reports Medicine (January 2023)
Article in International Journal of Applied Pharmaceutics (January 2023)